No. Wegovy (semaglutide) is an FDA-approved medication to treat obesity.
The outcomes vary based on the prescribed medication and individual medical history. In general, patients undergoing treatment with a GLP-1 medication can anticipate a weight loss of approximately 10-20% of their body weight.
The following people are not recommended to take GLP-1 agonist drugs.
- 1. Pregnant women
- 2. Nursing women
- 3. People with pancreatitis
- 4. Individuals with kidney impairment
- 5. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia
- 6. Type I Diabetes
- 7. Inflammatory bowel disease, Crohn disease or Ulcerative Colitis
Nausea, constipation, and other gastrointestinal discomfort are the most frequently encountered side effects.
GLP-1s are prescribed for prolonged usage, similar to other medications used to manage chronic conditions. Discontinuing the medication leads to an immediate cessation of its effects, and in most instances, some weight regain may occur. As you approach your desired healthy weight, it is advisable to consult with your healthcare provider regarding any necessary adjustments to the maintenance dose.